secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2026-05-11T20:58:18+00:00
Accession:  0001193125-26-217037
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q1 net loss $12.4M; cash $45.1M; icovamenib Phase II T2D data due Q4 2026
--------------------------------------------------------------------------------

- Net loss $12.4M ($1.6M SBC) vs $29.3M in Q1 2025; cash, equivalents & restricted cash $45.1M at Mar 31, 2026; runway into Q1 2027.
- R&D expenses $9.1M (down from $22.9M YoY); G&A $3.7M (down from $6.8M).
- Icovamenib chronic tox studies completed; Phase II T2D trials COVALENT-211/-212 dosing; topline 26-week data expected Q4 2026.
- Phase II T1D COVALENT-112: 52% C-peptide AUC increase at week 12 (200mg); preservation through week 52; plan for investigator-sponsored trial.
- Phase I GLP-1 obesity trial (BMF-650, GLP-131) ongoing; initial 28-day weight data expected Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/0001193125-26-217037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526217037/bmea-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-217037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer